Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CureVac N.V.
  6. News
  7. Summary
    CVAC   NL0015436031

CUREVAC N.V.

(CVAC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CUREVAC : Berenberg reaffirms its Buy rating

07/01/2021 | 04:25am EST

In a research note published by Zhiqiang Shu, Berenberg advises its customers to buy the stock. The target price is unchanged and still at USD 123.


© MarketScreener with dpa-AFX Analyser 2021
All news about CUREVAC N.V.
11/19CureVac's Q3 Pretax Loss Widens, Revenue Rises
MT
11/19CureVac To Begin Trials Of COVID-19 Vaccine As Animal Testing Shows Strong Antibody Res..
MT
11/18CureVac to begin trials for next-generation COVID-19 shots within months
RE
11/18CUREVAC N : Announces Financial Results for the Third Quarter and First Nine Months of 202..
PU
11/18CUREVAC N : Announces Financial Results for the Third Quarter and First Nine Months of 202..
PU
11/18CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021..
EQ
11/18CureVac Says Preclinical Trial Shows Antibody Levels of COVID-19 Vaccine Candidate CV2C..
MT
11/18CUREVAC N : Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, ..
PU
11/18CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, ..
EQ
11/18CureVac N.V. Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candida..
CI
More news
Analyst Recommendations on CUREVAC N.V.
More recommendations
Financials
Sales 2021 140 M 158 M 158 M
Net income 2021 -401 M -453 M -453 M
Net cash 2021 1 249 M 1 410 M 1 410 M
P/E ratio 2021 -17,9x
Yield 2021 -
Capitalization 5 956 M 6 726 M 6 723 M
EV / Sales 2021 33,7x
EV / Sales 2022 1,87x
Nbr of Employees 505
Free-Float 45,1%
Chart CUREVAC N.V.
Duration : Period :
CureVac N.V. Technical Analysis Chart | CVAC | NL0015436031 | MarketScreener
Technical analysis trends CUREVAC N.V.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 41,34 €
Average target price 56,82 €
Spread / Average Target 37,5%
EPS Revisions
Managers and Directors
Franz-Werner Haas Chief Executive Officer
Pierre Kemula Chief Financial Officer & Managing Director
Baron Jean Stéphenne Chairman-Supervisory Board
Mariola Fotin-Mleczek Chief Technology Officer
Igor Splawski Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
CUREVAC N.V.-42.42%6 726
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.81%24 431